ClinicalTrials.gg

Program

HRS-1780

A development code. Also written as “HRS-1780 tablet”, “HRS-1780 tablets” and “HRS-1780 Tablets”.

In Jiangsu HengRui Medicine's pipeline, Mineralocorticoid receptor. Its studies are mostly in Renal Insufficiency, Chronic · Hypertension · Hyperaldosteronism · Diabetes Mellitus, Type 2, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Feb 12, 20267 company-led studies, 6 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine76 open or runningphase 3since Feb 12, 2026Aug 7, 2023Nov 2026phase 2 · NCT07470983
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-1780, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2023First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT06039254 · 27 planned
  2. Mar 22, 2024Phase 1 study in Renal Insufficiency, ChronicNCT06344936 · 28 planned · China
  3. Jul 3, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06495931 · 24 enrolled · China
  4. Feb 12, 2026Phase 3 study in Renal Insufficiency, ChronicPhase 3 reachedNCT07419828 · 5,386 planned · China
  5. Mar 10, 2026Phase 2 study in HyperaldosteronismNCT07470983 · 61 enrolled · China
  6. Apr 22, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07557407 · 6 planned · China
  7. Jul 13, 2026Phase 3 study in Uncontrolled or Resistant HypertensionNCT07708441 · 914 planned · China

Ahead

  1. Nov 2026Primary completion: phase 2 study in HyperaldosteronismNCT07470983
  2. Apr 2029Primary completion: phase 3 study in Uncontrolled or Resistant HypertensionNCT07708441
  3. Apr 2030Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07419828

TargetBeta

“Mineralocorticoid receptor”the company's pipeline, read by Claude · source

Other programs on NR3C2

ProgramCompanyFurthest phaseStudies
finerenoneruleBayerphase 425
drospirenoneruleestetraphase 420
vamorolonerulereveragen-biopharma-incphase 411
Spironolactonerulecmp-development-llcphase 48
balcinrenoneruleAstraZenecaphase 315

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07708441Uncontrolled or Resistant Hypertension · China3RecruitingApr 2029914
NCT07557407Renal Insufficiency, Chronic · China1Not yet recruitingJun 20266
NCT07470983Hyperaldosteronism · China2Active, not recruitingNov 202661
NCT07419828Renal Insufficiency, Chronic · China3RecruitingApr 20305,386
NCT06495931Diabetes Mellitus, Type 2 · China1CompletedAug 13, 202424
NCT06344936Renal Insufficiency, Chronic · China1Not yet recruitingJul 202428
NCT06039254Renal Insufficiency, Chronic1Not yet recruitingNov 30, 202327

How it is read

Names in the registry

  • “HRS-1780 tablet”, 3 entries
  • “HRS-1780 tablets”, 2 entries
  • “HRS-1780 Tablets”, 1 entry
  • “[14C]HRS-1780”, 1 entry
  • “HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules”, 1 entry

Codes read as this program: HRS1780.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.